DUBLIN, April 24, 2014 /PRNewswire/ -- Jazz
Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will
report its 2014 first quarter financial results on Thursday, May 8, 2014, after the close of the
financial markets. Company management will host a live audio
webcast immediately following the announcement at 4:30 p.m. EDT/9:30 p.m.
IST to provide a business and financial update and discuss
first quarter 2014 financial results.
Interested parties may access the live audio webcast via the
Investors & Media section of the Jazz Pharmaceuticals website
at www.jazzpharmaceuticals.com. Please connect to the website prior
to the start of the conference call to ensure adequate time for any
software downloads that may be necessary to listen to the webcast.
A replay of the webcast will be archived on the website for one
week.
Audio webcast/conference call:
U.S. Dial-In Number: +1
866 318 8620
International Dial-In Number: +1 617 399 5139
Passcode: 38923320
A replay of the conference call will be available through
May 15, 2014 and accessible through
one of the following telephone numbers and entering the
passcode:
Replay U.S. Dial-In Number: +1 888 286 8010
Replay International Dial-In Number: +1 617 801 6888
Passcode: 77121089
About Jazz Pharmaceuticals
Jazz Pharmaceuticals
plc is a specialty biopharmaceutical company focused on
improving patients' lives by identifying, developing and
commercializing differentiated products that address unmet medical
needs. The company has a diverse portfolio of products and/or
product candidates in the areas of sleep, hematology/oncology, pain
and psychiatry. The company's U.S. marketed products in these areas
include: Xyrem® (sodium oxybate) oral solution, Erwinaze®
(asparaginase Erwinia chrysanthemi), Prialt® (ziconotide)
intrathecal infusion, Versacloz™ (clozapine) oral suspension,
FazaClo® (clozapine, USP) HD and FazaClo LD. Jazz
Pharmaceuticals also has a number of products marketed outside
the U.S., including Erwinase® and Defitelio®
(defibrotide). For more information, please
visit www.jazzpharmaceuticals.com.